Barinthus Biotherapeutics Expected to Post Significant Q1 Loss of 36 Cents Per Share
Summary
Analysts expect Barinthus Biotherapeutics to report a substantial loss of 36 cents per share for the quarter ending March 31, 2026, with no anticipated change in quarterly revenue. This projection follows the company's recent 10-K filing on March 13, 2026, which disclosed a $66.5 million net loss for 2025, zero revenue, and a Nasdaq delisting notice. The expected loss is highly material, representing over 50% of the current stock price of approximately $0.63, further highlighting the severe financial distress. Traders will be closely monitoring the actual Q1 results, expected around May 5, for confirmation of these estimates and any updates on the company's ongoing financial viability and delisting status.
At the time of this announcement, BRNS was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.7M. The 52-week trading range was $0.56 to $2.92. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.